Antithrombin-lowering in hemophilia: a closer look at fitusiran

Fitusiran: A Game-Changing Drug for Hemophilia Patients

Michael Makris on X: Robert Klamroth presented the results of the phase 3 Fitusiran study. This is siRNA inhibition of antithrombin in #hemophilia with no inhibitors. 90% reduction in ABR (Primary endpoint).

Hemophilia therapy: the future has begun

Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation

IJMS, Free Full-Text

Positive Phase III results for fitusiran in hemophilia

Fitusiran Substantially Reduces Hemophilia Bleeds with Simple Monthly Injection

Bleeding episodes significantly reduced in study of hemophilia drug

PDF) An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B